298 related articles for article (PubMed ID: 34009374)
1. Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients.
Kayama E; Shigeta K; Kikuchi E; Ogihara K; Hakozaki K; Iwasawa T; Kamisawa K; Kanai K; Ide H; Hara S; Mizuno R; Oya M
Jpn J Clin Oncol; 2021 Aug; 51(8):1303-1312. PubMed ID: 34009374
[TBL] [Abstract][Full Text] [Related]
2. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Matsumura Y; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
Int J Urol; 2022 Mar; 29(3):242-249. PubMed ID: 34902876
[TBL] [Abstract][Full Text] [Related]
3. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N
Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
5. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
6. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
7. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.
Iida K; Miyake M; Murakami K; Komiyama M; Okajima E; Sazuka T; Nishiyama N; Yasumoto H; Kimura T; Ito A; Shiga K; Yamagishi A; Kikuchi H; Sugimoto M; Taoka R; Kobayashi T; Kojima T; Kitamura H; Nishiyama H; Fujimoto K
Int J Clin Oncol; 2021 Nov; 26(11):2104-2112. PubMed ID: 34313904
[TBL] [Abstract][Full Text] [Related]
9. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
10. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.
Efiloğlu Ö; Bayrak Ö; Turan T; Kazan HÖ; Çulpan M; Çakıcı MÇ; Erturhan S; Yıldırım A
Arch Esp Urol; 2021 Nov; 74(9):875-882. PubMed ID: 34726624
[TBL] [Abstract][Full Text] [Related]
11. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.
Chade DC; Shariat SF; Godoy G; Savage CJ; Cronin AM; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2010 Jul; 184(1):74-80. PubMed ID: 20546806
[TBL] [Abstract][Full Text] [Related]
13. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
14. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
15. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
16. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
17. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
Miyamoto T; Miyake M; Toyoshima Y; Fujii T; Shimada K; Nishimura N; Iida K; Nakahama T; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Ohbayashi C; Fujimoto K
Int J Urol; 2021 Jul; 28(7):720-726. PubMed ID: 33734503
[TBL] [Abstract][Full Text] [Related]
19. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
20. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.
Hensley PJ; Bree KK; Brooks N; Matulay J; Li R; Nogueras-Gonzalez GM; Nagaraju S; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2022 Jun; 5(3):347-356. PubMed ID: 33935020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
